Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity

NCT00339001 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2006-06-20

No results posted yet for this study

Summary

To evaluate the possibility that erythropoietin with early iron supplementation may induce retinopathy of prematurity or worsen this disease. In addition risk factors for the development of ROP will be checked.

Conditions

  • Retinopathy of Prematurity

Interventions

DRUG

erythropoietin and early iron supplements

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Jacob Kuint, MD · Sheba Medical Center

Eligibility

Min Age
2 Weeks
Max Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Completion
2006-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00339001 on ClinicalTrials.gov